Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOZ73L)

• Drug Name: [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine Drug Info
• Synonyms: CHEMBL50492; 171783-25-8; 5-Ethyl-DMT; [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine; DTXSID30444736; BDBM50049099

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10775128
  CAS Number: CAS 171783-25-8
  TTD Drug ID: DMOZ73L

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Eletriptan	DMW649X	Migraine	8A80	Approved	[3]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[3]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[3]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[3]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[4]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[3]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[5]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[6]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[7]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[8]
Eletriptan	DMW649X	Migraine	8A80	Approved	[3]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[3]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[3]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[9]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[10]
Almogran	DM7I64Z	Migraine	8A80	Approved	[11]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[12]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[13]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Inhibitor	[1]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[1]

References

• [1] 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
• [2] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [5] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [6] Company report (NeurAxon)
• [7] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [8] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [9] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [10] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [11] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [12] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)